MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price

The latest update is out from MaxCyte ( (MXCT) ).

On March 16, 2026, MaxCyte, Inc. disclosed it had received notice from Nasdaq that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive trading days, putting it out of compliance with Nasdaq Global Select Market rules. The stock will continue trading while MaxCyte has until September 14, 2026, to regain compliance by lifting its closing bid to at least $1.00 for 10 straight sessions, with potential for an additional 180-day grace period or eventual delisting and appeal if it cannot meet the criteria, a development that raises uncertainty for shareholders and could affect the company’s capital market positioning.

The most recent analyst rating on (MXCT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.

Spark’s Take on MXCT Stock

According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.

MaxCyte’s financial challenges and valuation concerns weigh heavily on the stock’s score. However, strong shareholder support, strategic plans, and a solid cash position provide a basis for potential recovery, especially if operational efficiencies improve and macroeconomic conditions stabilize.

To see Spark’s full report on MXCT stock, click here.

More about MaxCyte

MaxCyte, Inc. is a biotechnology company whose common stock is listed on the Nasdaq Global Select Market, giving it access to public equity capital and visibility among life sciences investors. The company’s share price performance and compliance with Nasdaq listing standards are important for maintaining its market presence and investor confidence.

Average Trading Volume: 1,055,445

Technical Sentiment Signal: Sell

Current Market Cap: $80.27M

For an in-depth examination of MXCT stock, go to TipRanks’ Overview page.